139 related articles for article (PubMed ID: 12007845)
1. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Gillespie T; Masterton RG
Int J Antimicrob Agents; 2002 May; 19(5):377-82. PubMed ID: 12007845
[TBL] [Abstract][Full Text] [Related]
2. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
[TBL] [Abstract][Full Text] [Related]
3. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
MacGowan AP; Wootton M; Holt HA
J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa.
Segatore B; Setacci D; Perilli M; Franceschini N; Marchetti F; Amicosante G
Int J Antimicrob Agents; 2000 Jan; 13(3):223-6. PubMed ID: 10724029
[TBL] [Abstract][Full Text] [Related]
6. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
[TBL] [Abstract][Full Text] [Related]
7. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
Flynn CM; Johnson DM; Jones RN
J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
[TBL] [Abstract][Full Text] [Related]
8. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
Lister PD; Wolter DJ
Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
Garrison MW
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
[TBL] [Abstract][Full Text] [Related]
11. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
Bonfiglio G
Chemotherapy; 2001; 47(4):239-42. PubMed ID: 11399859
[TBL] [Abstract][Full Text] [Related]
12. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Hansen GT; Zhao X; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
14. [Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002].
De Vecchi E; Drago L; Nicola L; Colombo A; Guerra A; Tocalli L; Medaglia M; Gismondo MR
Infez Med; 2003 Dec; 11(4):196-200. PubMed ID: 14988667
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Pendland SL; Messick CR; Jung R
Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
[TBL] [Abstract][Full Text] [Related]
16. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
[TBL] [Abstract][Full Text] [Related]
17. An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Segatore B; Perilli M; Larosa M; Setacci D; Celenza G; Amicosante G
Int J Antimicrob Agents; 2007 Oct; 30(4):374-6. PubMed ID: 17659863
[No Abstract] [Full Text] [Related]
18. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
[No Abstract] [Full Text] [Related]
19. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
Firsov AA; Strukova EN; Portnoy YA; Shlykova DS; Zinner SH
Int J Antimicrob Agents; 2015 Sep; 46(3):313-8. PubMed ID: 26297633
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of quorum sensing system inhibits the resistance selection of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin in vitro.
Gao Y; Duan J; Geng X; Zhang Z; Zhang R; Li X; Wang S; Kang J; Yin D; Song Y
J Glob Antimicrob Resist; 2017 Sep; 10():113-119. PubMed ID: 28729210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
